Climb Bio Share Price Today

Deutsche Bank initiates Climb Bio with Buy rating, sets $28 target

Deutsche Bank initiated coverage on Climb Bio with a Buy rating. Analyst David Hoang set a price target of $28. The company trades on NASDAQ under the ticker CLYM.

Climb Bio to present Phase 2 budoprutug data at ASN Kidney Week

Climb Bio will present preliminary Phase 2 data for budoprutug in primary membranous nephropathy at ASN Kidney Week 2026. The PrisMN study data is selected for an oral presentation on October 24, 2026, in Denver. Phase 1 results for CLYM116 in healthy volunteers will be presented via posters on October 22 and 23, 2026. Budoprutug holds FDA Orphan Drug and Fast Track Designations for primary membranous nephropathy.

Climb Bio’s CLYM116 shows 29-day half-life in Phase 1 trial data

Phase 1 data shows CLYM116 has a projected half-life of approximately 29 days, three times longer than sibeprenlimab. Single 320 mg dose suppressed free APRIL by more than 90% and achieved 60% to 75% suppression of IgA through 12 weeks. No dose-limiting toxicities or serious adverse events were reported in the 46-volunteer study. Company plans to launch a Phase 3 study for IgA nephropathy in 2027 following NAVIGATE-2 data.

HC Wainwright reiterates Buy on Climb Bio, maintains $20 target

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Climb Bio (NASDAQ: CLYM) and maintained a $20 price target, indicating sustained confidence in the company's valuation.

Climb Bio launches $100M at-the-market common stock offering

Climb Bio has established a $100 million at-the-market offering program via Jefferies LLC, allowing for the periodic sale of common stock on the Nasdaq Global Market. The agreement, dated June 12, 2026, does not require Jefferies to sell a specific amount of securities. Shares are listed under the symbol CLYM, with a last reported sale price of $10.91 on June 11, 2026.

Climb Bio reports positive Phase 1b data for budoprutug in ITP

Climb Bio announced initial Phase 1b data for budoprutug in primary ITP patients, demonstrating robust B-cell depletion and durable platelet responses with a favorable safety profile. The study enrolled 15 patients across 250 mg and 500 mg dose cohorts, showing meaningful efficacy in heavily pretreated individuals. William Blair analyst Matt Phipps reiterated an Outperform rating, citing positive data and upcoming catalysts including CLYM116 data and further budoprutug results.